[Featured Stock] SK Bioscience Rises on US Clinical Phase 3 Approval for Pneumococcal Vaccine
Up 4.24% Compared to Previous Close
SK Bioscience is showing strong performance in early trading on the 20th following news that it has received approval for the Phase 3 clinical trial plan of its 21-valent pneumococcal vaccine (GBP410) in the United States.
As of 10:09 AM on the same day, SK Bioscience is trading at 51,600 KRW, up 4.24% from the previous close.
Hot Picks Today
"I Might End Up Paying My Entire Salary Just for Interest"... Annual Per-Person Interest Could Reach 6.73 Million Won, 'Yeongkeul-jok' Lament
- "Will I Really Be Left Out If I Don't Use It?"... The App Used by 23 Million Koreans Monthly, Is Naver Feeling the Pressure?
- [Infrastructure, From Construction to Replacement]⑪Maintenance Days Slashed from 58 to 5... Maintenance Know-How Grows Alongside
- Monami and ENEX See Stock Surge from 'Patriotic Theme'... Can the Rally Last?
- "Die from Heat or Starve": Amid Unprecedented Heatwave and Delivery Ban, Italian Riders Go on Strike
On the 17th, SK Bioscience announced that it had received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 clinical trial plan of the 21-valent pneumococcal vaccine, which is being developed in collaboration with Sanofi. The global clinical trial, recruiting 7,700 participants worldwide, began dosing its first subject last month.
![[Featured Stock] SK Bioscience Rises on US Clinical Phase 3 Approval for Pneumococcal Vaccine](http://www.asiae.co.kr/news/img_view.htm?img=2024072208164559128_1721603806.jpg)
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
